Traders should anticipate significant dilution from this offering and monitor for actual issuance of shares. The stock is likely to face downward pressure as the market prices in the dilutive capital raise. Watch for any updates on the BayMedica business and the company's ability to secure additional funding.
INM drugs
INM drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 23 $0.7610entry
- T+1 · 8mo ago −9.07%α −8.71% · $0.6920
- T+5 · 8mo ago −19.19%α −15.62% · $0.6150
- T+20 · 7mo ago −5.26%α −12.68% · $0.7210
- T+60 · 5mo ago +95.80%α +82.74% · $1.49
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
InMed Pharmaceuticals has filed an S-3 shelf registration statement allowing it to raise up to $50 million through future offerings of common shares, preferred shares, warrants, subscription rights, or units. This signals a potential capital raise, which could lead to significant shareholder dilution given the company's current $2 million market cap. The filing comes amid ongoing operating losses and substantial doubt about the company's ability to continue as a going concern, particularly due to adverse U.S. legislation impacting its BayMedica commercial business.
Key Financial Metrics
Key Facts
- InMed filed an S-3 shelf registration allowing for up to $50 million in future securities offerings.
- The company's market cap is only $2 million, meaning the offering could result in massive dilution of up to 2,500%.
- InMed has recurring operating losses and an accumulated deficit, with auditors noting substantial doubt about its ability to continue as a going concern.
- The company's BayMedica commercial business faces material adverse impact from recent U.S. legislation affecting its cannabinoid inventory.
- InMed expects its current cash of $7 million to last only until Q4 2026, creating urgency for additional financing.
Financial Impact
The $50 million offering could dilute existing shareholders by up to 2,500% given the current $2 million market cap. The company has $7 million in cash but is burning cash at a rate of approximately $4 million per six months.
Risk Factors
- Massive shareholder dilution from the $50 million offering against a $2 million market cap
- Substantial doubt about the company's ability to continue as a going concern
- Adverse U.S. legislation threatening the BayMedica commercial business
- Continuing operating losses and negative cash flow
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001213900-26-032416 |
| Document: ea028202601ex-fee.htm | 0001213900-26-032416 |
| Document: ea028202601ex5-1.htm | 0001213900-26-032416 |
| Document: ea028202601ex23-2.htm | 0001213900-26-032416 |
| Document: ea028202601ex23-1.htm | 0001213900-26-032416 |
| Document: 0001213900-26-032416-index-headers.html | 0001213900-26-032416 |
| Document: 0001213900-26-032416-index.html | 0001213900-26-032416 |
| Document: 0001213900-26-032416.txt | 0001213900-26-032416 |
| CONTEXT: 10-Q (2026-02-11) | 0001213900-26-014996 |
Track record
22 reports on INM
5 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +24.51% at T+1 after the Nov 3, 2026 report. 9 of 11 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $16.00 Now $19.87 +24.19% settles Dec 8
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
- Nov 3, 202613d ago 8-K Bearish 6/10 Entry $1.75 Now $19.87 −1035.43% settles Dec 3
- Nov 2, 202614d ago 425 Neutral 3/10 Entry $1.68 Now $19.87 +1082.74% settles Dec 2
- Oct 26, 202621d ago 425 Neutral 3/10 Entry $1.59 Now $19.87 +1149.69% settles Nov 24
- Oct 7, 20265w ago SC 13G/A Bullish 5/10 Entry $1.33 to $1.32 Now $19.87 +1393.99% ▼ −0.68% +4.61% vs SPY
- Oct 2, 20266w ago EFFECT Neutral 3/10 Entry $1.33 to $1.60 Now $19.87 +1393.99% ▲ +20.30% +22.11% vs SPY
- Sep 18, 20268w ago 8-K Bearish 6/10 Entry $1.38 to $1.37 Now $19.87 −1339.86% ▲ +1.06% +0.15% vs SPY
- Sep 9, 20269w ago 425 Neutral 6/10 Entry $1.31 to $1.33 Now $19.87 +1416.79% ▲ +1.53% −0.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers